Espero Pharmaceuticals Announces Exclusive Licensing and Distribution Agreement
Wednesday, September 16, 2015
September 16, 2015 08:30 AM Eastern Daylight Time
JACKSONVILLE, Fla.--(BUSINESS WIRE)--Espero Pharmaceuticals, Inc., (http://www.esperopharma.com) a privately held specialty pharmaceutical company, today announced the signing of an exclusive Licensing and Distribution Agreement with G. Pohl-Boskamp GmbH & Co. KG("Pohl-Boskamp"), a fully-integrated German pharmaceutical company with a 175 year operating history, for its new nitroglycerin sublingual powder formulation for acute relief of an attack or prophylaxis of angina pectoris for the U.S. market.
Pohl-Boskamp is the owner of the New Drug Application (NDA) for Nitrolingual® Pumpsprayapproved by the United States Food & Drug Administration (FDA) in 1997. Pohl-Boskamp has developed a newly patented formulation of nitroglycerin, nitroglycerin oral powder for sublingual administration. Nitroglycerin is a well-known NO-donator and sublingual routes in particular, are established for medicinal use in the U.S., the European Union and non-European countries, with recognized efficacy in patients with angina pectoris and an acceptable level of safety.
"Espero will assist our partner, Pohl-Boskamp, and support the submission of the NDA for this new nitroglycerin sublingual powder formulation to the FDA which is required for marketing approval," said Quang Pham, CEO.
"This is a major achievement for our company," said Marianne Boskamp, CEO of Pohl-Boskamp. "We believe our new formulation of nitroglycerin sublingual powder will be a more convenient method of delivery for both hospitals, clinicians and patients alike. We look forward to working with Espero as we seek FDA approval for our latest product."
Espero Pharmaceuticals, Inc., headquartered in Jacksonville, Florida, is an emerging growth specialty pharmaceutical company engaged in maximizing the commercial value of proven treatments that improve the quality of life for patients. Espero is focused on compounds with proven safety and efficacy administered via novel delivery solutions in the cardiovascular and other specialty therapeutic categories.
About G. Pohl-Boskamp GmbH & Co KG
Pohl-Boskamp is a privately owned business active in the international pharmaceutical market for 175 years with commercialized products in more than 45 countries. Pohl-Boskamp focuses on collaborating closely with partners abroad and developing products that positively impact patients' quality of life. It operates in numerous healthcare sectors including pneumology, urology, parasitology, cardiovascular diseases, gastroenterology, sleep disorders and dermatology. For more information visit http://www.pohl-boskamp.com/en/.
For Espero Pharmaceuticals, Inc.
MBS Value Partners, LLC
Betsy Brod, 212-661-2231
For more information, please visit http://esperopharma.com/.